BeiGene Ltd. ADR (BGNE): Price and Financial Metrics
BGNE Price/Volume Stats
| Current price | $148.56 | 52-week high | $266.67 |
| Prev. close | $144.12 | 52-week low | $126.97 |
| Day low | $146.16 | Volume | 409,300 |
| Day high | $152.83 | Avg. volume | 259,330 |
| 50-day MA | $154.48 | Dividend yield | N/A |
| 200-day MA | $176.43 | Market Cap | 14.21B |
BGNE Stock Price Chart Interactive Chart >
BeiGene Ltd. ADR (BGNE) Company Bio
BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. Founded in Beijing in 2010 by Xiaodong Wang and chief executive officer John V. Oyler, the company has offices in China, the United States, Australia and Europe. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor which became the first cancer drug developed in China to gain approval from the U.S. Food and Drug Administration when it received accelerated approval to treat mantle cell lymphoma in November 2019. (Source:Wikipedia)
Latest BGNE News From Around the Web
Below are the latest news stories about BEIGENE LTD that investors may wish to consider to help them evaluate BGNE as an investment opportunity.
12 High Growth International Stocks to BuyIn this article, we discuss the 12 high growth international stocks to buy. If you want to read about some more high growth international stocks, go directly to 5 High Growth International Stocks to Buy. There is general optimism on Wall Street that the Federal Reserve in the United States will be able to achieve […] |
FDA Approves Label Update for BRUKINSA® (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., December 22, 2023--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the U.S. Food and Drug Administration (FDA) has approved a label update for BRUKINSA® (zanubrutinib) to include superior progression-free survival (PFS) results from the Phase 3 ALPINE trial comparing BRUKINSA against IMBRUVICA® (ibrutinib) in previously treated patients with relapsed or refractory (R/R) chronic lymphocytic le |
3 Cancer-Focused Biotechs That Appear Promising Bets for 2024With the spotlight on oncology-focused companies in the biotech sector in 2023, we discuss three stocks that have a promising oncology portfolio/pipeline for 2024. |
BeiGene to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceBASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., December 21, 2023--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8th, 2024 with a presentation at 1:30 pm PT. |
13 Most Promising Healthcare Stocks According to AnalystsIn this article, we discuss the 13 most promising healthcare stocks according to analysts. To skip the detailed overview of the healthcare sector, go directly to the 5 Most Promising Healthcare Stocks According to Analysts. The healthcare industry landscape is changing. While the COVID-19 pandemic was one of the most significant events that led to […] |
BGNE Price Returns
| 1-mo | -4.20% |
| 3-mo | -8.24% |
| 6-mo | -12.84% |
| 1-year | -41.85% |
| 3-year | -54.07% |
| 5-year | 23.19% |
| YTD | -17.63% |
| 2023 | -18.00% |
| 2022 | -18.82% |
| 2021 | 4.85% |
| 2020 | 55.88% |
| 2019 | 18.18% |
Continue Researching BGNE
Want to see what other sources are saying about BeiGene Ltd's financials and stock price? Try the links below:BeiGene Ltd (BGNE) Stock Price | Nasdaq
BeiGene Ltd (BGNE) Stock Quote, History and News - Yahoo Finance
BeiGene Ltd (BGNE) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...